Physician profile
Miriam E Sciacchitano
NPI 1477807196
$9,705.12
in general payments reported to CMS, 2019-2025
26 companies · $2,987 in 2025
The $2,987 reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $681 · 2022: $353 · 2023: $575 · 2024: $5,109 · 2025: $2,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,270 · Food and Beverage: $2,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,270.00 |
| Food and Beverage | $2,400.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $6,587.59 | 2021-2025 | Nexplanon, Nuvaring |
| Abbvie INC. | $721.65 | 2021-2025 | |
| Exeltis, USA INC. | $323.33 | 2021-2025 | Slynd |
| Coopersurgical, INC. | $255.58 | 2021-2025 | Paragard T 380a, Paragard T 380a, Endosee |
| Pfizer INC. | $202.61 | 2023-2025 | |
| Shield Therapeutics INC | $179.91 | 2023-2025 | Accrufer |
| Biogen, INC. | $167.28 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $160.09 | 2022-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $128.13 | 2021-2025 | |
| Myriad Women'S Health, INC. | $122.25 | 2023 | Myrisk |
| Astellas Pharma US INC | $100.26 | 2024-2025 | Veozah |
| Avion Pharmaceuticals | $95.90 | 2021-2023 | Balcoltra |
| Bayer Healthcare Pharmaceuticals INC. | $83.50 | 2023-2025 | |
| Agile Therapeutics, INC. | $73.24 | 2021-2024 | Twirla |
| Myovant Sciences INC. | $73.06 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $68.65 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Exact Sciences Corporation | $68.18 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $64.80 | 2024 | Gardasil 9, Gardasil |
| Novo Nordisk INC | $43.88 | 2023-2025 | Wegovy |
| Seqirus USA INC | $40.37 | 2024-2025 | Flucelvax |
| Amgen INC. | $37.15 | 2024 | Evenity, Prolia |
| Dexcom, INC. | $34.46 | 2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $22.84 | 2021 | |
| Channel Medsystems, INC. | $21.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.52 | 2021 | |
| Aspira Women'S Health INC | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Sciacchitano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.